Brandywine Global Investment Management LLC Raises Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Brandywine Global Investment Management LLC increased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 13.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,390 shares of the biopharmaceutical company’s stock after purchasing an additional 4,820 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Vanda Pharmaceuticals were worth $189,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in VNDA. Geode Capital Management LLC increased its holdings in Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock valued at $6,689,000 after buying an additional 94,870 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Vanda Pharmaceuticals by 4.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 819,382 shares of the biopharmaceutical company’s stock valued at $3,925,000 after purchasing an additional 38,449 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after purchasing an additional 3,473 shares during the last quarter. Monaco Asset Management SAM boosted its position in Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after purchasing an additional 188,836 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Vanda Pharmaceuticals by 108.9% in the fourth quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company’s stock valued at $1,608,000 after purchasing an additional 175,019 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Down 3.1 %

NASDAQ VNDA opened at $4.37 on Friday. The stock has a market cap of $254.84 million, a price-to-earnings ratio of -13.66 and a beta of 0.69. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $6.75. The business has a fifty day moving average of $4.67 and a 200-day moving average of $4.73.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The firm had revenue of $53.19 million during the quarter, compared to the consensus estimate of $51.00 million. As a group, analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Wall Street Analyst Weigh In

VNDA has been the subject of several research reports. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction dated Friday, February 28th. The stock was acquired at an average price of $4.76 per share, with a total value of $47,600.00. Following the completion of the transaction, the chief executive officer now directly owns 2,361,730 shares in the company, valued at approximately $11,241,834.80. This trade represents a 0.43 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders have bought 32,000 shares of company stock valued at $151,180. Company insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.